RoboInd market brief: Pharmaceutical Collaborative Robots Market is estimated at USD 73.7 million in 2023. The report cites a CAGR of 9.7%.
Market snapshot
- USD 73.7 million in 2023
- USD 97 million in 2026
- USD 140.6 million in 2030
Stated compound annual growth rate: 9.7%.
Market overview
The global pharmaceutical collaborative robots market size was valued at USD 73.7 million in 2023 and is projected to grow from USD 97.0 million in 2026 to USD 140.6 million by 2030, at a CAGR of 9.7% from 2024 to 2030. The market in Asia Pacific dominated with a revenue share of 66.7% in 2023. In the pharmaceutical industry, the imperative of regulatory compliance and quality assurance underscores the need for precision in manufacturing processes. Collaborative robots are pivotal in ensuring compliance by reducing errors and inconsistencies and concurrently elevating product quality through controlled and consistent operations.
Market drivers and constraints
- Publicly stated market growth drivers: The pharmaceutical collaborative robots market is witnessing a surge in demand as the industry embraces automation to enhance efficiency and compliance. Rapid technological advancements have led to developing more versatile and user-friendly cobots that seamlessly integrate into pharmaceutical workflows. These robots are addressing challenges such as labor shortages, intricate regulatory requirements, and the need for flexible manufacturing.
Applications and segments
- Inspection of Pharmaceutical Drugs
- Public report segmentation list
- Pharmaceutical Companies
Competitive landscape
Public report coverage names Universal Robots A/S (Teradyne), Mitsubishi Electric Corporation, Kawasaki Heavy Industries Ltd, Yaskawa Electric Corporation, FANUC America Corporation. The list reflects participants identified by the source and is not a ranking.
Reading the figures: Values follow the market definition and forecast period stated in the source report. Estimates using different scopes should not be combined without normalization.